
Copernicus Therapeutics
Copernicus Therapeutics is a Cleveland clinical-stage biotechnology company advancing non-viral gene therapies on its STELLAR delivery platform.

Copernicus Therapeutics is a Cleveland clinical-stage biotechnology company advancing non-viral gene therapies on its STELLAR delivery platform.
copernicustherapeutics.comCrawled Oct 15, 2026
The company is a clinical-stage biotechnology company developing nucleic acid-based therapeutics using STELLAR, its re-dosable, non-viral delivery platform.
Northeastern University and Copernicus Therapeutics receive a $14.7 million NIDA/NIH grant to develop a gene therapy approach for treating opioid use disorder. Copernicus is identified as the industry co-recipient, partnering with Northeastern on the grant-funded development of the gene therapy approach.
Dec 2022 · Northeastern University Bouve CollegeNews article
Northeastern University and Cleveland-based Copernicus Therapeutics announce a $14.7 million grant from NIDA and NIH to develop a non-viral gene therapy approach for treating opioid use disorder. Their research will use Copernicus’ STELLAR delivery platform to pursue this gene therapy strategy.
Mar 2022 · PR NewswireNews article
Wize Pharma entered an exclusive license agreement with Case Western Reserve University for ophthalmic non-viral gene therapy technology. Copernicus Therapeutics is the exclusive sublicense holder for the licensed non-viral gene delivery platform.
Sep 2019 · PR NewswireNews article
The Foundation Fighting Blindness announces $8.25 million in funding for six gene therapy research projects. One project with Copernicus Therapeutics focuses on developing non-viral gene delivery for inherited retinal degenerative diseases.
Oct 2011 · Fierce BiotechNews article